Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265276 | 0.92 | TACR2 (0.55) | TACR2MCHR1 | |
| SCHEMBL4258141 | 0.88 | TACR2 (0.53) | TACR2MCHR1 | |
| SCHEMBL4261264 | 0.85 | KCNA3 (0.38) | TACR2 | |
| SCHEMBL4265200 | 0.84 | TACR2 (0.68) | TACR2 | |
| SCHEMBL5013720 | 0.83 | MCHR1 (0.52) | TACR2MCHR1 | |
| SCHEMBL6002420 | 0.83 | MCHR1 (0.52) | TACR2MCHR1 | |
| Hydrochloric Acid SCHEMBL4256200 | 0.82 | MCHR1 (0.51) | TACR2MCHR1 | |
| SCHEMBL4265273 | 0.77 | TACR2 (0.68) | TACR2 | |
| SCHEMBL5016489 | 0.76 | TACR2 (0.49) | TACR2MCHR1 | |
| SCHEMBL5802168 | 0.75 | TACR2 (0.65) | TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | TACR2 19/4885MCHR1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.